Telomir Pharmaceuticals Uncovers Promising Data on Telomir-1 for Prostate Cancer

Telomir Pharmaceuticals, Inc., based in Miami, disclosed new preclinical data revealing their lead candidate, Telomir-1, can significantly reduce PSA levels in human prostate cancer cells. PSA is a critical biomarker in assessing prostate cancer treatment responses, recognized by the FDA.

The study, conducted by SmartAssays, demonstrated Telomir-1's ability to lower PSA in androgen-responsive LNCaP cells, pivotal in prostate cancer biology. This aligns with previous findings where Telomir-1 showed a 50% reduction in tumor volume in non-androgen responsive cancer models.

The data suggests Telomir-1's potential across both hormone-responsive and hormone-resistant prostate cancer models. Telomir is advancing its preclinical program in various fields, including oncology and age-related diseases, aiming for future clinical trials.